Is CagriSema FDA-approved?

No. It remains in clinical development as of writing. Research-grade components are sold for laboratory use only.

How does CagriSema compare to tirzepatide?

Tirzepatide is a single dual-agonist molecule (GIP + GLP-1). CagriSema is two molecules covering GLP-1 and amylin. Phase III data shows competitive weight-loss outcomes.

Is it one injection or two?

It is being developed as a fixed-dose combination delivered as a single weekly subcutaneous injection.

Why combine amylin with GLP-1?

The pathways are complementary, not overlapping, which produces additive satiety signaling in research models.

What are the typical research protocols?

Once-weekly subcutaneous dosing aligned with semaglutide's pharmacokinetics.

Cagrilintide + Semaglutide

Also known as: CagriSema

Weight Loss & MetabolismBest known for: Amylin + GLP-1 combination weight-loss researchPopularity:

People searching for:

•what is CagriSema
•Cagrilintide Semaglutide combination
•CagriSema vs Tirzepatide
•amylin GLP-1 combination
•CagriSema research

Definition

Cagrilintide + Semaglutide(CagriSema)· Weight Loss & Metabolism: CagriSema is the 'two-pathway' approach to appetite: semaglutide reduces hunger via GLP-1, cagrilintide adds satiety via amylin. The combination is being studied as a head-to-head challenger to tirzepatide.

What is it?

CagriSema is the research shorthand for the fixed-dose combination of Cagrilintide (long-acting amylin analog) and Semaglutide (long-acting GLP-1 agonist), developed by Novo Nordisk and studied as a next-generation obesity therapy.

In plain English

CagriSema is the 'two-pathway' approach to appetite: semaglutide reduces hunger via GLP-1, cagrilintide adds satiety via amylin. The combination is being studied as a head-to-head challenger to tirzepatide.

How it works

Combines GLP-1 receptor agonism (reduced appetite, slowed gastric emptying, improved insulin secretion) with amylin and calcitonin receptor agonism (added satiety, glucagon suppression). The two mechanisms are non-overlapping, which underpins the additive effect.

What researchers study

•REDEFINE Phase III obesity trials
•Type 2 diabetes glycemic control
•Comparison with Tirzepatide
•Body-composition and lean-mass preservation
•Long-term cardiometabolic outcomes

What the internet talks about

Discussed in GLP-1 and obesity-research circles as the most-anticipated combination after tirzepatide. Forums track REDEFINE trial readouts closely; debate centers on whether the additive effect justifies the two-injection complexity.

Bro-science translation

“Semaglutide plus amylin — the appetite tag team.”

Commonly compared to

Cagrilintide + Semaglutide vs Tirzepatide Cagrilintide + Semaglutide vs Retatrutide

Common stack discussions

By design, it IS the stack. Comparative discussions almost always frame it against Tirzepatide and Retatrutide.

Related peptides

Semaglutide

The reference GLP-1 receptor agonist studied heavily for weight loss and glycemic control.

Cagrilintide

Long-acting amylin analog studied alongside GLP-1 agonists for added satiety.

Tirzepatide

Dual GLP-1 + GIP agonist studied for superior glycemic and weight outcomes vs single-agonists.

Retatrutide

Triple agonist studied for the most aggressive weight reduction signals in metabolic research.

Related categories

Weight Loss & Metabolism

Frequently asked questions

Quick summary

CagriSema is the research combination of Cagrilintide and Semaglutide, studied as a dual amylin + GLP-1 strategy for weight loss and metabolic research.